369 related articles for article (PubMed ID: 35462305)
1. The programmed site-specific delivery of LY3200882 and PD-L1 siRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironment.
Zhang P; Qin C; Liu N; Zhou X; Chu X; Lv F; Gu Y; Yin L; Liu J; Zhou J; Huo M
Biomaterials; 2022 May; 284():121518. PubMed ID: 35462305
[TBL] [Abstract][Full Text] [Related]
2. Synchronous targeted delivery of TGF-β siRNA to stromal and tumor cells elicits robust antitumor immunity against triple-negative breast cancer by comprehensively remodeling the tumor microenvironment.
Yang M; Qin C; Tao L; Cheng G; Li J; Lv F; Yang N; Xing Z; Chu X; Han X; Huo M; Yin L
Biomaterials; 2023 Oct; 301():122253. PubMed ID: 37536040
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of MYC suppresses programmed cell death ligand-1 expression and enhances immunotherapy in triple-negative breast cancer.
Li X; Tang L; Chen Q; Cheng X; Liu Y; Wang C; Zhu C; Xu K; Gao F; Huang J; Wang R; Guan X
Chin Med J (Engl); 2022 Oct; 135(20):2436-2445. PubMed ID: 36583862
[TBL] [Abstract][Full Text] [Related]
4. Tumor immunosuppression relief via acidity modulation combined PD-L1 siRNA for enhanced immunotherapy.
Tang Y; Chang Q; Chen G; Zhao X; Huang G; Wang T; Jia C; Lu L; Jin T; Yang S; Cao L; Zhang X
Biomater Adv; 2023 Jul; 150():213425. PubMed ID: 37084635
[TBL] [Abstract][Full Text] [Related]
5. Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer.
Yi M; Wu Y; Niu M; Zhu S; Zhang J; Yan Y; Zhou P; Dai Z; Wu K
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36460337
[TBL] [Abstract][Full Text] [Related]
6. Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy.
Yang Z; Sun JK; Lee MM; Chan MK
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36104100
[TBL] [Abstract][Full Text] [Related]
7. Improving anti-PD-L1 therapy in triple negative breast cancer by polymer-enhanced immunogenic cell death and CXCR4 blockade.
Zhou M; Luo C; Zhou Z; Li L; Huang Y
J Control Release; 2021 Jun; 334():248-262. PubMed ID: 33915224
[TBL] [Abstract][Full Text] [Related]
8. A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery.
Shadbad MA; Safaei S; Brunetti O; Derakhshani A; Lotfinejad P; Mokhtarzadeh A; Hemmat N; Racanelli V; Solimando AG; Argentiero A; Silvestris N; Baradaran B
Genes (Basel); 2021 Aug; 12(8):. PubMed ID: 34440380
[TBL] [Abstract][Full Text] [Related]
9. A nanodrug incorporating siRNA PD-L1 and Birinapant for enhancing tumor immunotherapy.
Gong T; Cai Y; Sun F; Chen J; Su Z; Shuai X; Shan H
Biomater Sci; 2021 Nov; 9(23):8007-8018. PubMed ID: 34714906
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.
Chatterjee S; Chatterjee A; Jana S; Dey S; Roy H; Das MK; Alam J; Adhikary A; Chowdhury A; Biswas A; Manna D; Bhattacharyya A
Carcinogenesis; 2021 Feb; 42(1):38-47. PubMed ID: 32832992
[TBL] [Abstract][Full Text] [Related]
11. Coadministration of iRGD peptide with ROS-sensitive nanoparticles co-delivering siFGL1 and siPD-L1 enhanced tumor immunotherapy.
Wan WJ; Huang G; Wang Y; Tang Y; Li H; Jia CH; Liu Y; You BG; Zhang XN
Acta Biomater; 2021 Dec; 136():473-484. PubMed ID: 34571271
[TBL] [Abstract][Full Text] [Related]
12. IR792-MCN@ZIF-8-PD-L1 siRNA drug delivery system enhances photothermal immunotherapy for triple-negative breast cancer under near-infrared laser irradiation.
Wang Y; Wang H; Song Y; Lv M; Mao Y; Song H; Wang Y; Nie G; Liu X; Cui J; Zou X
J Nanobiotechnology; 2022 Mar; 20(1):96. PubMed ID: 35236356
[TBL] [Abstract][Full Text] [Related]
13. Co-Delivery Nanomicelles for Potentiating TNBC Immunotherapy by Synergetically Reshaping CAFs-Mediated Tumor Stroma and Reprogramming Immunosuppressive Microenvironment.
Zhang Y; Han X; Wang K; Liu D; Ding X; Hu Z; Wang J
Int J Nanomedicine; 2023; 18():4329-4346. PubMed ID: 37545872
[TBL] [Abstract][Full Text] [Related]
14. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
[TBL] [Abstract][Full Text] [Related]
15. A size-shrinkable matrix metallopeptidase-2-sensitive delivery nanosystem improves the penetration of human programmed death-ligand 1 siRNA into lung-tumor spheroids.
Wen J; Qiu N; Zhu Z; Bai P; Hu M; Qi W; Liu Y; Wei A; Chen L
Drug Deliv; 2021 Dec; 28(1):1055-1066. PubMed ID: 34078185
[TBL] [Abstract][Full Text] [Related]
16. Nanoparticle-integrated dissolving microneedles for the co-delivery of R848/aPD-1 to synergistically reverse the immunosuppressive microenvironment of triple-negative breast cancer.
Huang S; Wen T; Wang J; Wei H; Xiao Z; Li B; Shuai X
Acta Biomater; 2024 Mar; 176():344-355. PubMed ID: 38244662
[TBL] [Abstract][Full Text] [Related]
17. Mitochondrial Disruption Nanosystem Simultaneously Depressed Programmed Death Ligand-1 and Transforming Growth Factor-β to Overcome Photodynamic Immunotherapy Resistance.
Jiang X; Yi L; Li C; Wang H; Xiong W; Li Y; Zhou Z; Shen J
ACS Nano; 2024 Jan; 18(4):3331-3348. PubMed ID: 38227812
[TBL] [Abstract][Full Text] [Related]
18. Loss of RBMS1 promotes anti-tumor immunity through enabling PD-L1 checkpoint blockade in triple-negative breast cancer.
Zhang J; Zhang G; Zhang W; Bai L; Wang L; Li T; Yan L; Xu Y; Chen D; Gao W; Gao C; Chen C; Ren M; Jiao Y; Qin H; Sun Y; Zhi L; Qi Y; Zhao J; Liu Q; Liu H; Wang Y
Cell Death Differ; 2022 Nov; 29(11):2247-2261. PubMed ID: 35538152
[TBL] [Abstract][Full Text] [Related]
19. Carbon nanotubes (CNT)-loaded ginsenosides Rb3 suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer.
Luo X; Wang H; Ji D
Aging (Albany NY); 2021 Jun; 13(13):17177-17189. PubMed ID: 34111025
[TBL] [Abstract][Full Text] [Related]
20. A hierarchical tumor-targeting strategy for eliciting potent antitumor immunity against triple negative breast cancer.
Lin M; Cai Y; Chen G; Zhong H; Li B; Li T; Xiao Z; Shuai X
Biomaterials; 2023 May; 296():122067. PubMed ID: 36854221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
